Tyra Biosciences (TYRA) Earnings Date & Reports

Key Takeaways

• Tyra Biosciences is expected to report its third-quarter 2026 results after the market closes on November 4, 2026, with the conference call scheduled for 4:00 p.m. Eastern Time.
• Wall Street consensus calls for a net loss of approximately $0.67 per share, compared with a loss of $0.50 per share in the same quarter a year ago.
• As a clinical-stage biotech, the company is expected to report zero product revenue, so investors will focus on cash burn, operating expenses, and pipeline milestones rather than sales.
• Research and development (R&D) spending has climbed as Tyra advances its lead FGFR3 inhibitor, dabogratinib, across multiple Phase 2 trials.
• The company ended its most recent quarter with a cash runway extending into the second half of 2028, providing meaningful financial flexibility.
• Tyra has missed consensus EPS estimates in its last two reported quarters, raising the bar for this release.
• For deeper context, explore Major News, Today's Price Move, Price Targets, and Forecast on Tickeron's dedicated pages for TYRA.
• You can also explore Trending AI Robots to see how automated strategies are positioning across the market.

Earnings Context and Why It Matters

For a pre-revenue biotechnology company, quarterly earnings are less about top-line growth and more about execution, spending discipline, and clinical momentum. Tyra Biosciences is developing precision medicines targeting Fibroblast Growth Factor Receptor (FGFR) biology — proteins involved in cell growth that are implicated in certain cancers and genetically defined bone conditions. Because the company generates no product sales, investors read its results primarily as a signal of how efficiently management is deploying capital and how quickly its pipeline is advancing. With multiple Phase 2 readouts expected across 2026, this report offers a timely checkpoint on both the balance sheet and the broader development strategy.

Earnings Expectations

Analysts expect Tyra to post a net loss of roughly $0.67 per share for the third quarter of 2026, within a consensus estimate range of approximately $0.76 to $0.60. That compares with a loss of $0.50 per share in the prior-year quarter. Revenue is expected to remain at zero, consistent with the company's clinical-stage status.

Recent quarters have trended below expectations. In the second quarter of 2026, Tyra reported a loss of $0.69 per share, missing the $0.65 consensus, and recorded a GAAP (Generally Accepted Accounting Principles) net loss of about $45.6 million. R&D expenses rose to roughly $39.2 million as the company accelerated enrollment across its dabogratinib studies. For the full fiscal year 2026, the Street models a loss of approximately $2.68 per share. Given that two straight quarters came in short of estimates, investors will be watching whether the company's spending trajectory and loss per share align with forecasts this time.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool designed to help traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is built to surface trade ideas, trending stocks, breakout candidates, and broader market opportunities more efficiently than manual screening. For those tracking names like TYRA alongside their peers, the AI Screener offers a structured way to compare setups and identify signals across sectors.

Market Reaction and Investor Sentiment

Sentiment heading into this release reflects a mixture of pipeline optimism and earnings-related caution. Wall Street analysts maintain a broadly bullish stance, with a consensus rating of Strong Buy and an average price target well above recent trading levels. However, the stock has struggled since its August 2026 report, when shares fell sharply after a wider-than-expected loss. The stock's post-earnings announcement drift since that release has been negative, suggesting investors are demanding clearer evidence that rising spending is translating into near-term clinical value. Key risk factors include the timing and durability of upcoming Phase 2 data, continued operating-loss growth, and any unexpected delays in trial enrollment.

Forward Outlook and Key Factors to Monitor

The most important catalysts for Tyra extend well beyond a single quarter's income statement. Management has described 2026 as a pivotal year, with several data readouts expected across its pipeline of FGFR-targeting medicines.

At the center of the story is dabogratinib, the company's lead FGFR3-selective inhibitor. Investors are watching its Phase 2 trials closely, including BEACH301 in pediatric achondroplasia (ACH), a genetic condition that affects bone growth, and SURF302 in FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer (NMIBC). A related study, SURF303, is expected to begin dosing patients with low-grade upper tract urothelial carcinoma (LG-UTUC), a cancer of the upper urinary tract, during 2026.

Beyond dabogratinib, Tyra is advancing TYRA-430, an FGFR4/3-biased inhibitor in hepatocellular carcinoma (HCC), the most common form of liver cancer, and TYRA-200, an FGFR1/2/3 inhibitor in intrahepatic cholangiocarcinoma (ICC), a rare bile-duct cancer. Enrollment progress and any early safety or efficacy signals in these programs could shape sentiment.

From a financial standpoint, the key variable to monitor is the pace of R&D spending against the company's cash runway, which extends into the second half of 2028. As long as losses remain funded, attention will stay fixed on whether upcoming clinical readouts validate the pipeline and support the stock's premium valuation.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations